The healing process after glaucoma filtration is the main determinant of surgical failure and, even more important, the final intraocular pressure. The ability to fully control wound healing may ultimately give us the ability to set the intraocular pressure in the low teens for all patients undergoing glaucoma filtration surgery. The authors review the changes in how to use antimetabolites to improve safety, and many of the exciting new areas of progress, including growth factor neutralization and future molecular therapies to control wound healing. Increasing evidence indicates that intraocular pressure (IOP) in the low teens best preserves vision in glaucoma, even when the IOP is within the "normal'' range [1, 2] . The major determinant of the final IOP after most forms of filtration surgery is the healing response of the eye and the body. Simply, if the healing response could be accurately controlled, then most patients could achieve an IOP of 10 mm Hg after an operation, the current "holy grail'' of glaucoma surgery. At present, this level of IOP control is most consistently achieved by filtration surgery combined with antimetabolites.
Although the use of antimetabolites has revolutionized glaucoma surgery, particularly in patients with a high risk of surgical failure because of scarring, blinding complications exist that are associated with the use of these agents. This is particularly the case if antimetabolites are to be used in all patients undergoing surgery [3••] where the risk of complications such as endophthalmitis appears to be increased. The use of these agents requires modifications of surgery to ensure a safe outcome. In addition, some patients still fail surgery, despite the use of high concentrations of strong antimetabolites. Therefore, continued research in the area of healing modification is necessary, which is leading to further advances in our understanding of healing processes and ultimately better outcomes for patients after glaucoma surgery.
The events after glaucoma surgery can be summarized and simplified as shown in Table 1 . Scarring after surgery can be reduced by modulating different parts of the healing response.
Preoperative tissue and cellular activation
Studies from our center have suggested that conjunctival cellular "activation'' may help to explain the association of poor outcome in patients on long-term topical therapy undergoing filtration surgery [4, 5] . A number of mechanisms may exist that change the fibroblast phenotype leading to activation of a fibrotic response [6] . The state of cellular activation may also affect the response to antiscarring agents, including antimetabolites [7] . Recent studies have confirmed increased preoperative conjunctival cells in patients with higher IOP after surgery [8] .
We have also demonstrated that, although antimetabolites can alter the degree of fibroblast activation, treated 
Surgical trauma
It is logical to reduce surgical trauma, particularly the release of blood, which contains many elements that are stimulatory to healing including growth factors. However, although it has been suggested that certain methods of surgery are less likely to cause trauma (eg, laser sclerostomy, small tube implants, or deep sclerectomy), no evidence suggests that any of these procedures escape the scarring response of the human body. The long-term results suggest that healing continues, with a gradual reduction in long-term success even with subscleral surgery [11-13].
Inflammation
Persistent conjunctival inflammation is associated with an enhanced scarring response ( Fig. 1 ). Even subclinical inflammation may be important. For instance, combined cataract and glaucoma surgery has a worse prognosis than glaucoma surgery alone. We have shown that laser flare readings are persistently higher after cataract surgery compared with trabeculectomy, even in clinically quiet eyes, which may help to explain the effect of cata-ract surgery on healing [14•]. This finding fits with the observation that phacoemulsification can raise the pressure in eyes with ocular hypotonia after mitomycin C (MMC)-assisted glaucoma filtration surgery [15••]. Conjunctival epithelial cells may continue to express HLA-DR several months after surgery, which may increase the ability of these cells to induce immune inflammation and fibrosis [16] .
Corticosteroids have been shown to suppress the local inflammatory response, both experimentally [17] and
Figure 1. Persistent inflammation
Persistent inflammation, which is associated with a continued wound healing response and scarring after glaucoma filtration surgery. Recent work suggests that activated fibroblasts can prevent T-cells from apoptozing. clinically. Topical corticosteroid treatment after trabeculectomy is associated with a significant reduction in final IOP [18] . The role of nonsteroidal antiinflammatory drugs (NSAIDs) is still uncertain [19] . Newer agents affecting aspects of the inflammation pathway (eg, cyclooxygenase-2) may also be useful [20] . Another agent modulating inflammatory cell activity is cyclosporine, which may have a role in preventing scarring.
Fibrin formation
Fibrinolytic agents (eg, tissue plasminogen activator and urokinase) have been used to lyse blood clots after surgery [21, 22] . In the short term, fibrinolytic agents may lower IOP buy lysing clot but a risk still exists of further extra-and intraocular hemorrhage [23] . Furthermore, the breakdown molecules may have a long-term stimulatory effect on wound healing. More promising may be agents that prevent the formation of fibrin such as heparin, which in combination with intraoperative 5-fluorouracil (5-FU) reduces the rate of proliferative vitreoretinopathy (PVR) in patients at high risk [24••].
Growth factors/cytokines
The aqueous contains a large number of small molecules that stimulate cells known as growth factors or cytokines (used historically when we investigated them in conjunction with inflammatory cells) which can all stimulate wound healing [25,26•]. Interferon-␣, an antifibrotic cytokine, has been shown to reduce scarring activity of fibroblasts, although a clinical trial did not show it to be significantly better than current antimetabolites [27] . However, one growth factor, transforming growth factor-␤, (TGF-␤) stimulates more activity than the other growth factors [28, 29] . TGF-␤ may even neutralize the effect of MMC in vivo [28,30•,31] .
Several agents currently being tested clinically may act on growth factors including TGF-␤. Tranilast ((N-(3Ј,4Јdimethoxycinnamoyl)anthranilic acid) inhibits TGF-␤ activity, and has been shown to have antiscarring effects in the body and the eye. In experimental models, it has been shown to effectively inhibit scarring in experimental PVR [32], and photorefractive keratectomy [33] . Early results also suggest it decreases conjunctival scarring following application in glaucoma filtration surgery. Other agents suppressing growth factor activity include genistein [34], and suramin, the latter recently being found to reduce postoperative scarring in an in vivo model of filtration surgery [35] .
We have investigated different methods of targeting TGF-␤ activity, including the use of a novel neutralizing antibody. CAT-152 (Cambridge Antibody Technology, Melbourn, UK) is a fully human monoclonal antibody specific to the active form of human TGF-␤ 2 , which is the predominant form in the eye. Preclinical studies in our laboratory have shown its efficacy in vitro and in vivo.
In an animal model of aggressive conjunctival scarring, it significantly improved glaucoma filtration surgery outcome compared with control [36••]. Compared with the effects of MMC treatment histologically, it appeared much less destructive to local tissue. A phase I/II twocenter study of this antibody in glaucoma filtration surgery has shown no significant side effects or inflammatory reaction and, possibly, some benefit compared with placebo in a masked randomized clinical study [37] (Fig.  2) . Larger scale, multicenter studies are now continuing.
Other methods of neutralizing growth factors include blocking gene expression of a growth factor or its receptor. This can be done using a sequence of DNA complementary to the gene sequence of the growth factor (antisense oligonucleotide [OGN]), which Cordeiro et al. have recently shown may reduce scarring in a model of conjunctival healing [38] . Other molecular strategies, such as the use of ribozyme technology which destroy the specific growth factor RNA, also allow a more specific and targeted strategy to reduce scarring [39•].
Cellular proliferation and other wound healing activities
The antimetabolites 5-FU and MMC continue to be the backbone of antiscarring treatments. Although subconjunctival 5-FU was the first widespread antimetabolite regimen used [40] , intraoperative regimens of MMC [41] or 5-FU [42] have gained favor because of the convenience, supplemented by 5-FU injections [43•]. However, both treatments are associated with relatively small treatment areas resulting in the production of thin avascular blebs with complications including leakage, hypotony, and endophthalmitis with long-term follow-up [3]. Although methods have been described to treat these thin, leaking blebs, including more recent combi- nations of compression sutures and blood [44] or Nd-YAG-induced subconjunctival bleeding [45], these methods are not entirely satisfactory.
Strategies to minimize the incidence of complications associated with antimetabolite use in glaucoma filtration surgery include optimizing the choice of agent, method of application, and the surgical technique. These factors include restricting their use by adopting a strategy based on different single-application antiscarring agents and concentrations "titrated'' against patient risk factors. This is particularly important if patients have a lower risk of scarring but still require lower target pressures such as in normal tension glaucoma. In a study from our unit, although intraoperative MMC lowered IOP more than intraoperative 5-FU, many more complications occurred with MMC, which illustrates the importance of choosing the right agent and dose [46••]. Our regimen is shown in Table 2 .
The time of exposure varies among different surgeons and centers. In a recent study, we showed that tissue uptake rises sharply and then peaks at about 3 minutes, with only a small rise after that [47•]. Varying the concentration appears to be a more accurate way of determining tissue uptake rather than volume [48] . Therefore, we adhere to a fixed exposure time and vary concentration for different risk groups. Other ways may exist to enhance uptake with electric pulse targeted drug delivery system [49] .
The area of application is important. One important parameter that our group has shown to greatly influence bleb morphology and survival, is that of MMC treatment area size; small treatment areas giving rise to thin-walled and cystic blebs were seen in comparison with the more diffuse-looking, thicker walled blebs associated with a large treatment areas [50] . Based on experimental work, we have altered our application to ensure a large MMC treatment area with many more diffuse noncystic blebs (Fig. 3) . It may also be clinically advantageous to apply intraoperative antimetabolites under the scleral flaps (but before entering the anterior chamber) as well as under the conjunctiva, as shown by El-Sayyad et al. in a randomized study [51••] . As long as the anterior chamber is not entered earlier, concerns about ciliary body toxicity do not seem to have been borne out clinically. The use of photosensitizing drugs, coupled with diffuse blue light to kill fibroblasts, may also be an interesting way to control both the treatment surface area and healing [52] . However, the effect of these agents on the overlying epithelium may also be important, as differentiated, stable epithelium may have a suppressive effect on fibroblasts in the wound [53•].
Other potential pathways, such as intracellular transcription [54] , genes controlling proliferation (eg, p21 [55] ), or integrins and their receptors [56] , can be antagonized in vitro to inhibit fibroblast activity.
Cellular migration, wound contraction, matrix synthesis, and remodeling
A number of agents can affect the cytoskeleton of the cell and, hence, inhibit migration, including paclitaxel etoposide (microtubule-stabilizing agents) and cytochalasin B (a microfilament inhibitor). Paclitaxel and etoposide used in models of filtration surgery were found to prolong bleb survival [57] , although neither have been assessed in a large clinical trial. *Intraoperative ␤-radiation 1000 cGy can also be used. Most of the newer agents currently being tested in pilot studies (eg, CAT-152 humanized anti-TGF-␤ 2 antibody) are probably appropriate for the lowand intermediate-risk groups. These groups do, however, account for most patients undergoing glaucoma filtration surgery. † Postoperative 5-FU injections can be given in addition to the intraoperative applications of antimetabolite. Lower target pressures would suggest a stronger agent was required.
Figure 3. Picture of child who had received high-dose MMC intraoperatively in both eyes
The patient's left eye, with the cystic raised, encapsulated cystic bleb, has had a smaller area of treatment with a limbus-based conjunctival flap. The eye on the right, with a diffuse noncystic bleb, has had a large area of treatment with a fornix-based conjunctival flap.
It is known that cell migration is intrinsically involved in contraction. Hence, any aforementioned antimigration agent would also inhibit contraction. The matrix metalloproteinase (MMP), an enzyme that degrade extracellular matrix, has also been shown to be involved in cell-mediated contraction. The levels of MMP in the aqueous relate to the development of retinal scarring [58] . The importance of these levels has been demonstrated by the fact that collagen contraction can be inhibited using MMP inhibitors [59] . Lathyrogenic agents (eg, ␤-aminopropionitrile and D-penicillamine) primarily interfere with molecular crosslinking of collagen. Experimental and clinical evidence indicate that they may work in filtration surgery [60] , although their use has not been pursued.
Apoptosis and termination of healing
Wound healing is probably terminated by apoptosis [61] , although little is currently known about the physiologic signals initiating fibroblast apoptosis. However, our laboratory demonstrated that MMC and high doses of 5-FU induce fibroblast apoptosis, in addition to their inhibiting proliferation [62] . However, fibroblasts that are not killed but merely growth arrested by MMC can keep Tlymphocytes from causing apoptosis, which would result in a persistent inflammation [63] . Proapoptotic peptides induce death in only targeted cells by means of a homing motif. These peptides have been suggested to have antiproliferative activity in mice [64] . Therefore, the induction and regulation of apoptotic mechanisms potentially offer a novel way of regulating wound healing.
Conclusion
Control of the healing process would ultimately allow determination of the long-term final IOP in patients after glaucoma filtration surgery. With our increase in understanding of the healing process and developments in modern science, including cell and molecular biology, our ability to control healing safely will continue to improve. :586-590. Reviews three groups of patients with normal tension glaucoma having surgery without antimetabolite, intraoperative 5-FU, or intraoperative MMC, respectively. Although the patients with MMC had the lowest final pressures, the complications were felt to be too high and the use of intraoperative 5-FU recommended as the standard adjunctive agent in this group of patients. 
